A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Clinical trial NCT03524612 · COMPLETED

Trial details

NCT number: NCT03524612
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenic Purpura (ITP)

Start date: 2018-11-02
Primary completion: 2021-10-22
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.